Considering the inconsistent responses reported in previously published articles, the clinical efficacy of ALK‐TKIs including alectinib for lung cancer patients with uncommon ALK gene fusions remained to be evaluated with more cases and the comprehensive molecular profiling of tumours could assist precise treatment beyond canonical examinations such as IHC. The gene discussed is ALK; the disease is lung carcinoma.